Literature DB >> 7943108

Amniotic fluid volume reflects recent glycemic status in gestational diabetes mellitus.

I Bar-Hava1, S A Scarpelli, Y Barnhard, M Y Divon.   

Abstract

OBJECTIVE: Our purpose was to determine the association between amniotic fluid volume and recent glucose status in gestational diabetes. STUDY
DESIGN: Serial amniotic fluid index values, mean blood glucose levels, and percent hyperglycemia (> or = 120 mg/dl) 1 day and 1 week before the ultrasonographic examinations were prospectively collected in 399 gestational diabetics. Patients demonstrating at least one amniotic fluid index measurement within the normal range (i.e., 5 cm < amniotic fluid index < or = 20 cm) and at least one elevated measurement (i.e., amniotic fluid index > 20 cm) formed the study group. With each patient serving as her own control, glucose index values preceding normal and elevated amniotic fluid index values were compared.
RESULTS: Significantly higher mean blood glucose values 1 day (114.7 mg/dl vs 102.8 mg/dl, p < 0.01) and 1 week before (111.0 mg/dl vs. 102.0 mg/dl, p < 0.05) were calculated for examinations resulting in elevated amniotic fluid index values compared with normal amniotic fluid index values, respectively. Similarly, significantly higher percents of hyperglycemia 1 day (32% vs 16.5%, p < 0.05) but not 1 week (30.8% vs 21.7%, p > 0.05) before the elevated amniotic fluid index were documented.
CONCLUSION: Amniotic fluid volume reflects recent glycemic status in gestational diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943108     DOI: 10.1016/s0002-9378(94)70066-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Hydramnios Associated with Foetal Duodenal Atresia.

Authors:  Shakti Vardhan; R C Behra; Tony Jose; Aby Koshy
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Diagnosis and Management of IUGR in Pregnancy Complicated by Type 1 Diabetes Mellitus.

Authors:  Paweł Gutaj; Ewa Wender-Ozegowska
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.